Compare CCLD & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCLD | RFL |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | 3650 | N/A |
| Industry | Computer Software: Prepackaged Software | Real Estate |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.0M | 92.6M |
| IPO Year | N/A | 2017 |
| Metric | CCLD | RFL |
|---|---|---|
| Price | $2.19 | $2.57 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 326.9K | 230.3K |
| Earning Date | 05-07-2026 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | $11.49 | N/A |
| Revenue Next Year | $7.95 | N/A |
| P/E Ratio | $32.04 | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $2.09 | $1.12 |
| 52 Week High | $4.01 | $2.80 |
| Indicator | CCLD | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 36.88 | 75.69 |
| Support Level | N/A | $1.22 |
| Resistance Level | $2.40 | N/A |
| Average True Range (ATR) | 0.11 | 0.26 |
| MACD | 0.00 | 0.11 |
| Stochastic Oscillator | 5.26 | 79.33 |
CareCloud Inc delivers flexible, tech-enabled solutions for healthcare providers of all sizes and multi-specialties across the U.S. It is a healthcare technology company offering cloud-based solutions that simplify clinical, administrative, and financial workflows for medical practices of all sizes. Its comprehensive suite includes Electronic Health Records (EHRs), Practice Management, Revenue Cycle Management (RCM), Medical Billing, Telehealth, and Patient Experience solutions. The group helps practices increase efficiency, improve patient care, and drive sustainable growth-all while ensuring HIPAA compliance and seamless integration. The operating segments of the group are Healthcare IT, which is the key revenue-generating segment, and Medical Practice Management.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.